Minnow Medical Bolsters Management Team
LAGUNA HILLS, Calif., Oct. 6 /PRNewswire/ -- Minnow Medical, Inc., a developer of a novel platform technology employing radiofrequency thermoplasty for the treatment of in-stent restenosis and other peripheral vascular conditions, announced today the appointment of two veteran medical device executives.
Prabodh Mathur has been named chief product development officer and Michael K. Handley has been named vice president of quality, clinical and regulatory affairs.
"Both Prabodh and Michael are experts in their respective fields and have the experience, drive and passion to assist Minnow in executing the remaining clinical, regulatory and product development activities necessary to gain clearance for the use of our ZCath™ System to treat occlusions in the leg arteries of patients with peripheral vascular disease," said Raymond W. Cohen, CEO of Minnow. "Minnow's technology has already been proven to be safe in human clinical studies in Europe. The goal of the new management team is to become one of the first companies to establish efficacy and gain U.S. Food and Drug Administration (FDA) clearance to treat patients who have already received stent implants in their peripheral leg arteries and are suffering from in-stent restenosis - a dangerous build-up of plaque inside the stents."
About the Executives:Mathur is a seasoned technical executive with a proven track record of developing complex, innovative, Class III medical devices from concept, through design exploration, IP review, engineering, manufacturing transfer, regulatory clearance to market launch. Mathur held numerous engineering leadership positions, including chief technical officer, with publicly traded Cardiac Science over a 15-year period until 2009. Earlier, Mathur was, for nine years, vice president engineering of Medstone International, a manufacturer of transportable lithotripters.
Over the past years, Mathur has been involved in developing products incl